BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 9339955)

  • 1. Predictions of mathematical models of tissue oxygenation and generation of singlet oxygen during photodynamic therapy.
    Yuan J; Mahama-Relue PA; Fournier RL; Hampton JA
    Radiat Res; 1997 Oct; 148(4):386-94. PubMed ID: 9339955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Photofrin photobleaching for singlet oxygen dose estimation during photodynamic therapy of MLL cells in vitro.
    Dysart JS; Patterson MS
    Phys Med Biol; 2005 Jun; 50(11):2597-616. PubMed ID: 15901957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dynamic model for ALA-PDT of skin: simulation of temporal and spatial distributions of ground-state oxygen, photosensitizer and singlet oxygen.
    Liu B; Farrell TJ; Patterson MS
    Phys Med Biol; 2010 Oct; 55(19):5913-32. PubMed ID: 20844331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calculation of singlet oxygen dose from photosensitizer fluorescence and photobleaching during mTHPC photodynamic therapy of MLL cells.
    Dysart JS; Singh G; Patterson MS
    Photochem Photobiol; 2005; 81(1):196-205. PubMed ID: 15469385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluence rate as a modulator of PDT mechanisms.
    Henderson BW; Busch TM; Snyder JW
    Lasers Surg Med; 2006 Jun; 38(5):489-93. PubMed ID: 16615136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of photosensitizer dose on fluence rate responses to photodynamic therapy.
    Wang HW; Rickter E; Yuan M; Wileyto EP; Glatstein E; Yodh A; Busch TM
    Photochem Photobiol; 2007; 83(5):1040-8. PubMed ID: 17880498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Photofrin photodynamic therapy can significantly deplete or preserve oxygenation in human basal cell carcinomas during treatment, depending on fluence rate.
    Henderson BW; Busch TM; Vaughan LA; Frawley NP; Babich D; Sosa TA; Zollo JD; Dee AS; Cooper MT; Bellnier DA; Greco WR; Oseroff AR
    Cancer Res; 2000 Feb; 60(3):525-9. PubMed ID: 10676629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Photodynamic therapy creates fluence rate-dependent gradients in the intratumoral spatial distribution of oxygen.
    Busch TM; Wileyto EP; Emanuele MJ; Del Piero F; Marconato L; Glatstein E; Koch CJ
    Cancer Res; 2002 Dec; 62(24):7273-9. PubMed ID: 12499269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy can be enhanced by the use of a low dose of photofrin in human tumor xenografts.
    Peng Q; Warloe T; Moan J; Godal A; Apricena F; Giercksky KE; Nesland JM
    Cancer Res; 2001 Aug; 61(15):5824-32. PubMed ID: 11479222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of oxygen monitoring during photodynamic therapy and its potential for treatment dosimetry.
    Woodhams JH; Macrobert AJ; Bown SG
    Photochem Photobiol Sci; 2007 Dec; 6(12):1246-56. PubMed ID: 18046479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring of singlet oxygen is useful for predicting the photodynamic effects in the treatment for experimental glioma.
    Yamamoto J; Yamamoto S; Hirano T; Li S; Koide M; Kohno E; Okada M; Inenaga C; Tokuyama T; Yokota N; Terakawa S; Namba H
    Clin Cancer Res; 2006 Dec; 12(23):7132-9. PubMed ID: 17145838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-linking of signal transducer and activator of transcription 3--a molecular marker for the photodynamic reaction in cells and tumors.
    Henderson BW; Daroqui C; Tracy E; Vaughan LA; Loewen GM; Cooper MT; Baumann H
    Clin Cancer Res; 2007 Jun; 13(11):3156-63. PubMed ID: 17545518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Photofrin photodynamic therapy: 2.0 mg/kg or not 2.0 mg/kg that is the question.
    Allison RR; Sibata CH
    Photodiagnosis Photodyn Ther; 2008 Jun; 5(2):112-9. PubMed ID: 19356641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of fluence rate on tumor and normal tissue responses to photodynamic therapy.
    Sitnik TM; Henderson BW
    Photochem Photobiol; 1998 Apr; 67(4):462-6. PubMed ID: 9559590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of drug-light-interval on photodynamic therapy of port wine stains--simulation and validation of mathematic models.
    Huang N; Cheng G; Li X; Gu Y; Liu F; Zhong Q; Wang Y; Zen J; Qiu H; Chen H
    Photodiagnosis Photodyn Ther; 2008 Jun; 5(2):120-6. PubMed ID: 19356642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling of a type II photofrin-mediated photodynamic therapy process in a heterogeneous tissue phantom.
    Hu XH; Feng Y; Lu JQ; Allison RR; Cuenca RE; Downie GH; Sibata CH
    Photochem Photobiol; 2005; 81(6):1460-8. PubMed ID: 15960591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Photodynamic therapy and cancer: a brief sightseeing tour.
    Palumbo G
    Expert Opin Drug Deliv; 2007 Mar; 4(2):131-48. PubMed ID: 17335411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing the efficiency of photodynamic therapy by improved light delivery and oxygen supply using an anticoagulant in a solid tumor model.
    Yang L; Wei Y; Xing D; Chen Q
    Lasers Surg Med; 2010 Sep; 42(7):671-9. PubMed ID: 20740620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma.
    Ferrario A; von Tiehl KF; Rucker N; Schwarz MA; Gill PS; Gomer CJ
    Cancer Res; 2000 Aug; 60(15):4066-9. PubMed ID: 10945611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of photodynamic therapy antitumor activity in mice by nitric oxide synthase inhibition is fluence rate dependent.
    Henderson BW; Sitnik-Busch TM; Vaughan LA
    Photochem Photobiol; 1999 Jul; 70(1):64-71. PubMed ID: 10420844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.